MedTrace Logo

Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

NCT03967249 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2023-03-22

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of extended dosing with IONIS GHR-LRx in participants with acromegaly as add-on to somatostatin receptor ligands (SRL) therapy.

Conditions

Interventions

DRUG

IONIS GHR-LRx

Participants will receive IONIS GHR-LRx by subcutaneous injection.

DRUG

Somatostatin Receptor Ligand (SRL)

Participants will receive Somatostatin Receptor Ligand (lanreotide, octreotide) once monthly.

Sponsors & Collaborators

  • Ionis Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-25
Primary Completion
2022-03-31
Completion
2022-07-07
FDA Drug
Yes

Countries

  • United States
  • Hungary
  • Lithuania
  • Poland
  • Russia
  • Serbia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03967249 on ClinicalTrials.gov